Loading clinical trials...

Westlake Aging Cohort (WeAC) | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Westlake Aging Cohort (WeAC)

Westlake Aging Cohort

NCT07373444•Westlake University

Summary

The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.

Detailed Description

The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.

Eligibility

Age

55 - 90 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Age between 55 and 90 years (inclusive) at baseline.
•2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
•3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
•4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
•5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
•6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.

Exclusion Criteria

•1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
•2. Current use of psychoactive medications or any other drugs that may affect the study.
•3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
•4. Participants with any other diseases that may affect the study.

Locations (2)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

Hangzhou Third People's Hospital

Hangzhou, Zhejiang, China

Key Dates

Start Date

January 1, 2026

Primary Completion Date

December 31, 2030

Completion Date

December 31, 2031

Last Updated

January 28, 2026

Enrollment

2,800

ESTIMATED participants

Conditions

AgingCognition ImprovementCognition DisordersCognition

Contacts

Ju-Sheng Zheng, PhD

CONTACT

86-0571-86915303 zhengjusheng@westlake.edu.cn

Targeting Aging With a Ketone Ester for Function in Frailty

NCT06645847

Frail ElderlyAging+2 more

View study

RECRUITING

Ultrasound Image Bank: Advancing Medical Research and Diagnostics

NCT07031921

Gynecological ImagingUltrasound Diagnostics+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Westlake Aging Cohort (WeAC)

Inclusion Criteria

Exclusion Criteria

Targeting Aging With a Ketone Ester for Function in Frailty

Ultrasound Image Bank: Advancing Medical Research and Diagnostics

MRI Study of Musculoskeletal Function

Skin Barrier Function and Inflammation in Aging: The BIA Study

Studies Into Touch in Healthy Humans to Provide Sensory Feedback in Prostheses

Safe-Age Study: A Safety and Tolerability Study of a Nutritional Supplement in Healthy Older Adults